Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key ...

Syngene International, in collaboration with the Research and Innovation Circle of Hyderabad (RICH) and Biocon Foundation, has announced the launch of the third cohort of its flagship women-in-STEM ...

The stock’s current performance reflects a positive investor response, with Biocon demonstrating promising financial results ...

The European Commission (EC) has approved Biocon Biologics’ biosimilars referencing Amgen’s bone disease therapy denosumab.

Prestige Estates Projects Ltd., Ashok Leyland Ltd., and Biocon Ltd. are three midcap stocks with 'buy' recommendations on ...

Bangalore: Biocon has announced the appointment of Ekta Agarwal as the Interim Company Secretary and Compliance Officer ...

On July 9, even when the 90-day pause of Liberation Day ended, Nifty Pharma jumped by over 101 points before correcting.

Biocon share price gained 2.5 per cent after reports suggested that the company is planning to file for generic versions of ...

The pharma sector will be in focus on July 9, after Donald Trump said that he would make an announcement on pharmaceuticals ...

Biocon Biologics receives marketing authorizations for Vevzuo and Evfraxy biosimilars for bone-related diseases in the UK.

The company is seeking regulatory approval of generic Ozempic by September from Canadian authorities, along with other ...

Biocon Biologics Ltd received UK approval for Vevzuo and Evfraxy, biosimilars of Denosumab. Vevzuo is approved for ...